Cardiol Therapeutics (CRDL) Total Liabilities (2020 - 2026)

Cardiol Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• Quarterly Total Liabilities fell 4.2% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 4.2% YoY) and the FY2025 annual result came in at $4.1 million, down 19.38% from the prior year.
• Total Liabilities was $5.3 million for Q1 2026 at Cardiol Therapeutics, up from $4.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $9.0 million in Q2 2022 and bottomed at $2.5 million in Q3 2025.
• A 5-year average of $6.2 million and a median of $6.1 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 265.3% — and 2025, when it sank 52.64%.
• Cardiol Therapeutics' Total Liabilities stood at $7.2 million in 2022, then slipped by 14.22% to $6.2 million in 2023, then retreated by 17.75% to $5.1 million in 2024, then declined by 19.38% to $4.1 million in 2025, then increased by 27.56% to $5.3 million in 2026.
• Business Quant data shows CRDL's Total Liabilities at $5.3 million in Q1 2026, $4.1 million in Q4 2025, and $2.5 million in Q3 2025.